Comprehensive genomic profiling to inform targeted therapy selection is a central part of oncology care. However, the volume and complexity of alterations uncovered through genomic profiling make it difficult for oncologists to choose the most appropriate therapy for their patients. Here, we present a solution to this problem, The Molecular Registry of Tumors (MRT) and our Molecular Tumor Board (MTB). PATIENTS AND METHODS: MRT is an internally developed system that aggregates and normalizes genomic profiling results from multiple sources. MRT serves as the foundation for our MTB, a team that reviews genomic results for all Duke University Health System cancer patients, provides notifications for targeted therapies, matches patients to biomarker-driven trials, and monitors the molecular landscape of tumors at our institution. RESULTS: Among 215 patients reviewed by our MTB over a 6-month period, we identified 176 alterations associated with therapeutic sensitivity, 15 resistance alterations, and 51 alterations with potential germline implications. Of reviewed patients, 17% were subsequently treated with a targeted therapy. For 12 molecular therapies approved during the course of this work, we identified between two and 71 patients who could qualify for treatment based on retrospective MRT data. An analysis of 14 biomarker-driven clinical trials found that MRT successfully identified 42% of patients who ultimately enrolled. Finally, an analysis of 4,130 comprehensive genomic profiles from 3,771 patients revealed that the frequency of clinically significant therapeutic alterations varied from approximately 20% to 70% depending on the tumor type and sequencing test used. CONCLUSION: With robust informatics tools, such as MRT, and the right MTB structure, a precision cancer medicine program can be developed, which provides great benefit to providers and patients with cancer.
Comprehensive genomic profiling to inform targeted therapy selection is a central part of oncology care. However, the volume and complexity of alterations uncovered through genomic profiling make it difficult for oncologists to choose the most appropriate therapy for their patients. Here, we present a solution to this problem, The Molecular Registry of Tumors (MRT) and our Molecular Tumor Board (MTB). PATIENTS AND METHODS: MRT is an internally developed system that aggregates and normalizes genomic profiling results from multiple sources. MRT serves as the foundation for our MTB, a team that reviews genomic results for all Duke University Health System cancer patients, provides notifications for targeted therapies, matches patients to biomarker-driven trials, and monitors the molecular landscape of tumors at our institution. RESULTS: Among 215 patients reviewed by our MTB over a 6-month period, we identified 176 alterations associated with therapeutic sensitivity, 15 resistance alterations, and 51 alterations with potential germline implications. Of reviewed patients, 17% were subsequently treated with a targeted therapy. For 12 molecular therapies approved during the course of this work, we identified between two and 71 patients who could qualify for treatment based on retrospective MRT data. An analysis of 14 biomarker-driven clinical trials found that MRT successfully identified 42% of patients who ultimately enrolled. Finally, an analysis of 4,130 comprehensive genomic profiles from 3,771 patients revealed that the frequency of clinically significant therapeutic alterations varied from approximately 20% to 70% depending on the tumor type and sequencing test used. CONCLUSION: With robust informatics tools, such as MRT, and the right MTB structure, a precision cancer medicine program can be developed, which provides great benefit to providers and patients with cancer.
Authors: Paul A Harris; Robert Taylor; Robert Thielke; Jonathon Payne; Nathaniel Gonzalez; Jose G Conde Journal: J Biomed Inform Date: 2008-09-30 Impact factor: 6.317
Authors: Jason Zhu; Matthew Tucker; Daniele Marin; Rajan T Gupta; Patrick Healy; Michael Humeniuk; Casey Jarvis; Tian Zhang; Megan McNamara; Daniel J George; Yuan Wu; Stacey Lisi; Andrew J Armstrong Journal: Urol Oncol Date: 2019-07-19 Impact factor: 3.498
Authors: Amber Johnson; Yekaterina B Khotskaya; Lauren Brusco; Jia Zeng; Vijaykumar Holla; Ann M Bailey; Beate C Litzenburger; Nora Sanchez; Md Abu Shufean; Sarina Piha-Paul; Vivek Subbiah; David Hong; Mark Routbort; Russell Broaddus; Kenna R Mills Shaw; Gordon B Mills; John Mendelsohn; Funda Meric-Bernstam Journal: JCO Precis Oncol Date: 2017-09-13
Authors: Todd C Knepper; Gillian C Bell; J Kevin Hicks; Eric Padron; Jamie K Teer; Teresa T Vo; Nancy K Gillis; Neil T Mason; Howard L McLeod; Christine M Walko Journal: Oncologist Date: 2017-02-08
Authors: Robert C Doebele; Alexander Drilon; Luis Paz-Ares; Salvatore Siena; Alice T Shaw; Anna F Farago; Collin M Blakely; Takashi Seto; Byung Chul Cho; Diego Tosi; Benjamin Besse; Sant P Chawla; Lyudmila Bazhenova; John C Krauss; Young Kwang Chae; Minal Barve; Ignacio Garrido-Laguna; Stephen V Liu; Paul Conkling; Thomas John; Marwan Fakih; Darren Sigal; Herbert H Loong; Gary L Buchschacher; Pilar Garrido; Jorge Nieva; Conor Steuer; Tobias R Overbeck; Daniel W Bowles; Elizabeth Fox; Todd Riehl; Edna Chow-Maneval; Brian Simmons; Na Cui; Ann Johnson; Susan Eng; Timothy R Wilson; George D Demetri Journal: Lancet Oncol Date: 2019-12-11 Impact factor: 41.316
Authors: Alexander Drilon; Geoffrey R Oxnard; Daniel S W Tan; Herbert H F Loong; Melissa Johnson; Justin Gainor; Caroline E McCoach; Oliver Gautschi; Benjamin Besse; Byoung C Cho; Nir Peled; Jared Weiss; Yu-Jung Kim; Yuichiro Ohe; Makoto Nishio; Keunchil Park; Jyoti Patel; Takashi Seto; Tomohiro Sakamoto; Ezra Rosen; Manisha H Shah; Fabrice Barlesi; Philippe A Cassier; Lyudmila Bazhenova; Filippo De Braud; Elena Garralda; Vamsidhar Velcheti; Miyako Satouchi; Kadoaki Ohashi; Nathan A Pennell; Karen L Reckamp; Grace K Dy; Jürgen Wolf; Benjamin Solomon; Gerald Falchook; Kevin Ebata; Michele Nguyen; Binoj Nair; Edward Y Zhu; Luxi Yang; Xin Huang; Elizabeth Olek; S Michael Rothenberg; Koichi Goto; Vivek Subbiah Journal: N Engl J Med Date: 2020-08-27 Impact factor: 91.245
Authors: Wassim Abida; Akash Patnaik; David Campbell; Jeremy Shapiro; Alan H Bryce; Ray McDermott; Brieuc Sautois; Nicholas J Vogelzang; Richard M Bambury; Eric Voog; Jingsong Zhang; Josep M Piulats; Charles J Ryan; Axel S Merseburger; Gedske Daugaard; Axel Heidenreich; Karim Fizazi; Celestia S Higano; Laurence E Krieger; Cora N Sternberg; Simon P Watkins; Darrin Despain; Andrew D Simmons; Andrea Loehr; Melanie Dowson; Tony Golsorkhi; Simon Chowdhury Journal: J Clin Oncol Date: 2020-08-14 Impact factor: 44.544